Claude Messiaen

992 total citations
14 papers, 628 citations indexed

About

Claude Messiaen is a scholar working on Genetics, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Claude Messiaen has authored 14 papers receiving a total of 628 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Genetics, 5 papers in Molecular Biology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Claude Messiaen's work include Genomics and Rare Diseases (6 papers), Biomedical Text Mining and Ontologies (3 papers) and Oral and gingival health research (3 papers). Claude Messiaen is often cited by papers focused on Genomics and Rare Diseases (6 papers), Biomedical Text Mining and Ontologies (3 papers) and Oral and gingival health research (3 papers). Claude Messiaen collaborates with scholars based in France, Belgium and United States. Claude Messiaen's co-authors include Paul Landais, Pierre Quartier, Olivier Richer, A. Duquesne, Damien Chaussabel, Rolando Cimaz, Xavier Bossuyt, A. Mogenet, Jean‐Marc Tréluyer and Jacques Bienvenu and has published in prestigious journals such as Journal of Bone and Mineral Research, Annals of the Rheumatic Diseases and Journal of the American Medical Informatics Association.

In The Last Decade

Claude Messiaen

14 papers receiving 616 citations

Peers

Countries citing papers authored by Claude Messiaen

Since Specialization

Citations

This map shows the geographic impact of Claude Messiaen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claude Messiaen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claude Messiaen more than expected).

Fields of papers citing papers by Claude Messiaen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claude Messiaen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claude Messiaen. The network helps show where Claude Messiaen may publish in the future.

Co-authorship network of co-authors of Claude Messiaen

This figure shows the co-authorship network connecting the top 25 collaborators of Claude Messiaen. A scholar is included among the top collaborators of Claude Messiaen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claude Messiaen. Claude Messiaen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	New insights into epidemiological data and impact of the COVID-19 pandemic on IgA vasculitis in children and adults: a French nationwide cohort 2023 ·Rheumatology International ·(unknown), (unknown), (unknown), Claude Messiaen, Anne‐Sophie Jannot, Bénédicte Sautenet, Jean‐Michel Halimi, F. Maillot, Évangéline Pillebout, Alexandra Audemard‐Verger	8
2	Impact of the COVID-19 pandemic on the care of rare and undiagnosed diseases patients in France: a longitudinal population-based study 2022 ·Orphanet Journal of Rare Diseases ·Louis Soussand, Mathieu Kuchenbuch, Claude Messiaen, Arnaud Sandrin, Anne‐Sophie Jannot, Rima Nabbout	7
3	Age at diagnosis in patients with chronic congenital endocrine conditions: a regional cohort study from a reference center for rare diseases 2021 ·Orphanet Journal of Rare Diseases ·(unknown), Claude Messiaen, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Muriel Houang, Bruno Donadille, Carine Courtillot, Gianpaolo De Filippo, Jean‐Claude Carel, Sophie Christin‐Maître, Philippe Touraine, Irène Netchine, Michel Polak, Juliane Léger	3
4	The ongoing French BaMaRa-BNDMR cohort: implementation and deployment of a nationwide information system on rare disease 2021 ·Journal of the American Medical Informatics Association ·Anne‐Sophie Jannot, Claude Messiaen, (unknown), (unknown), Arnaud Sandrin, (unknown)	13
5	Healthcare trajectory of children with rare bone disease attending pediatric emergency departments 2020 ·Orphanet Journal of Rare Diseases ·David Dawei Yang, Geneviève Baujat, Antoine Neuraz, Nicolas Garcelon, Claude Messiaen, Arnaud Sandrin, G. Chéron, Anita Burgun, Zagorka Péjin, Valérie Cormier‐Daire, François Angoulvant	1
6	Federating patients identities: the case of rare diseases 2018 ·Orphanet Journal of Rare Diseases ·(unknown), Paul Landais, Claude Messiaen, Marie‐Christine Jaulent, Rémy Choquet	6
7	Prevalence of fibrodysplasia ossificans progressiva (FOP) in France: an estimate based on a record linkage of two national databases 2017 ·Orphanet Journal of Rare Diseases ·Geneviève Baujat, Rémy Choquet, S. Bouée, Viviane Jeanbat, (unknown), (unknown), Caroline Michot, Kim‐Hanh Le Quan Sang, (unknown), Claude Messiaen, Paul Landais, Valérie Cormier‐Daire	66
8	Management of rare diseases of the Head, Neck and Teeth: results of a French population-based prospective 8-year study 2017 ·Orphanet Journal of Rare Diseases ·(unknown), Rémy Choquet, (unknown), (unknown), Claude Messiaen, (unknown), Marie‐Paule Vazquez, Ariane Berdal, Corinne Alberti, Muriel de La Dure‐Molla	6
9	Prognostic Factors From an Epidemiologic Evaluation of Fibrous Dysplasia of Bone in a Modern Cohort: The FRANCEDYS Study 2016 ·Journal of Bone and Mineral Research ·(unknown), D. Gensburger, Claude Messiaen, Roland Chapurlat	35
10	Patient Information, Consentsand Privacy Protection Scheme for an Information System Dedicated to Pervasive Developmental Disorders 2014 ·Studies in health technology and informatics ·Mohamed Said, Laurence Robel, Claude Messiaen, (unknown), Jean Philippe Jaïs, Bernard Golse, Paul Landais	2
11	A methodology for a minimum data set for rare diseases to support national centers of excellence for healthcare and research 2014 ·Journal of the American Medical Informatics Association ·Rémy Choquet, (unknown), (unknown), Claude Messiaen, (unknown), Paul Landais	55
12	A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial) 2010 ·Annals of the Rheumatic Diseases ·Pierre Quartier, Florence Allantaz, Rolando Cimaz, Pascal Pillet, Claude Messiaen, Christophe Bardin, Xavier Bossuyt, Anne Boutten, Jacques Bienvenu, A. Duquesne, Olivier Richer, Damien Chaussabel, A. Mogenet, Jacques Banchereau, Jean‐Marc Tréluyer, Paul Landais, Virginia Pascual	381
13	CEMARA an information system for rare diseases 2010 ·Studies in health technology and informatics ·Paul Landais, Claude Messiaen, Ana Rath, Loïc Le Mignot, Éric Dufour, Mohamed Said, Jean-Philippe Jaı̈s, Laurent Toubiana, Geneviève Baujat, E. Bourdon‐Lanoy, Marion Gérard‐Blanluet, Christine Bodemer, Rémi Salomon, (unknown), Martine Le Merrer, Alain Verloès	27
14	CEMARA: a Web dynamic application within a N-tier architecture for rare diseases. 2008 ·PubMed ·Claude Messiaen, Loïc Le Mignot, Ana Rath, Jean‐Baptiste Richard, Éric Dufour, Mohamed Said, (unknown), Alain Verloès, Martine Le Merrer, Christine Bodemer, Geneviève Baujat, Marion Gérard‐Blanluet, E. Bourdon‐Lanoy, Rémi Salomon, Ségolène Aymé, Paul Landais	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact